ClinicalTrials.gg
CompletedNCT03312751Updated Mar 12, 2024Results posted

Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

A Phase 3 interventional study of Emapalumab in Primary Hemophagocytic Lymphohistiocytosis, sponsored by Swedish Orphan Biovitrum. Completed at 27 sites in 8 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States — 11 open to participants now, 19 under way, 1 of them phase 3. Lymphohistiocytosis, Hemophagocytic · United States.

Enrollment
13th of 32
35 · median 21
Started
2019
with 1 other
Phase 3
Only one
of the 42
Registered
26th of 42
by date
Lead sponsor
8 of 42
Swedish Orphan Biovitrum

Among the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 3, and was the 26th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

11 of the 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Lymphohistiocytosis, Hemophagocytic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to expand the knowledge on the efficacy and safety of emapalumab (previously known as NI-0501) as a treatment for primary haemophagocytic lymphohistiocytosis (HLH) patients, including on long-term outcomes and quality of life assessments. Emapalumab can be administered as the first-line therapy to patients not previously treated with the current standard of care, or can be given to patients who have either failed or were unable to tolerate the available standard of care.

Emapalumab is to be administered until the start of conditioning for hematopoietic stem cell transplantation (HSCT), with an anticipated duration ranging from a minimum of 4 weeks to approximately 12 weeks and not exceeding 6 months.

After treatment completion, patients will continue in the study for long-term follow-up until 1 year after either HSCT or last emapalumab infusion (if HSCT is not performed).

03

Conditions studied

  • Primary Hemophagocytic Lymphohistiocytosis

Keywords

  • Interferon-gamma
  • NI-0501
  • primary HLH
  • emapalumab
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Primary HLH patients with active disease.
  • Treatment naïve patients or patients having already received HLH conventional therapy, but having not responded, not achieved a satisfactory response or worsened, or reactivated, or are unable to tolerate current standard of care.
  • signed by the patient or by the patient's legally authorized representative.
  • Received guidance on .

Main Exclusion Criteria:

  • Diagnosis of secondary HLH consequent to a proven rheumatic, metabolic or neoplastic disease.
  • Active mycobacteria, Histoplasma capsulatum, Shigella, Salmonella, Campylobacter or Leishmania infections.
  • Evidence of latent tuberculosis.
  • Presence of .
  • Concomitant disease or malformation severely affecting cardiovascular, pulmonary, central nervous system (CNS), liver, or renal function, that in the opinion of the Investigator may significantly affect the likelihood to respond to treatment and/or the assessment of emapalumab safety and/or efficacy.
  • History of or allergy to any component of the study regimen.
  • Receipt of a BCG vaccine within 12 weeks prior to Screening.
  • Receipt of a live or attenuated-live (other than BCG) vaccine within 6 weeks prior to Screening.
  • Pregnant or lactating female patients.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Emapalumab

    Drug: Emapalumab

Interventions

  • Emapalumab will be administered by intravenous infusion, twice weekly.

06

What researchers measure

Primary outcomes

  1. Overall Response at Week 8 or End of Treatment (if Earlier)

    The overall response rate (ORR) of patients achieving either Complete or Partial Response or HLH Improvement, at Week 8 or EOT (whichever occurs earlier).

    Time frame: Up to Week 8

Secondary outcomes

  1. Overall Survival at End of Study

    Number of patients surviving to the end of the study.

    Time frame: Up to 18 months

  2. Overall Survival to HSCT

    Number of patients surviving to HSCT.

    Time frame: From start of treatment to HSCT or from start of treatment until 1 year after EOT for patient who did not undergo HSCT

  3. Overall Survival for Patients Receiving HSCT

    Number of patients surviving post HSCT.

    Time frame: Up to 1 year post HSCT

  4. Event-free Survival

    Number of patients experiencing event-free survival, the duration of which was defined as time from HSCT to date of (whichever occurs first): death from any cause, graft failure, or HLH reactivation.

    Time frame: Up to 1 year post HSCT

  5. Overall Response at Start of Conditioning

    Number of patients achieving either a Complete or Partial Response or HLH Improvement, at start of conditioning (or at last emapalumab infusion if HSCT is not performed).

    Time frame: Up to 6 months

  6. Duration of Response

    Duration of response, i.e., maintenance of the response achieved at any time during the study (with censoring time at start of conditioning for patients with no event) calculated only for patients showing confirmed overall response. Summarized by number of patients experiencing each category of response duration.

    Time frame: Up to 18 months

  7. Time to Response

    Time to first response at any time during the study.

    Time frame: Up to 18 months

  8. Number of Patients Reducing Glucocorticoids by 50% or More of the Baseline Dose During Emapalumab Treatment

    Number of patients able to reduce glucocorticoids by 50% or more of the baseline dose during emapalumab treatment.

    Time frame: Up to 6 months

  9. Number of Patients Proceeding to HSCT

    Number of patients able to proceed to HSCT when deemed indicated.

    Time frame: Up to 18 months

  10. Quality of Life Assessed Through PedsQL™, Pediatric Quality of Life Inventory™

    Assessment of the quality of life using the PedsQL "Pediatric Quality of Life Inventory". The PedsQL uses a 100-point scale ranging from 0 to 100 with higher values indicating better quality of life.

    Time frame: Up to 6 months

  11. Quality of Life Assessed Through Behavioral, Affective and Somatic Experiences Scales (BASES)

    Assessment of the quality of life using the BASES questionnaire, which is a validated 38-item questionnaire; a reduced nonvalidated 22-item version of the questionnaire is used in an exploratory nature for the secondary endpoint. Subscale scores were calculated using a 5-point Likert scale from 1 to 5 for all questions. Scores for all questions in each subscale were added up and divided by the number of patients in the analysis population to reach the mean score. Subscale scores were calculated for the following domains: * Physical Discomfort (5 questions, '1' = best response, total range 5-25) * Cooperation/Compliance (5 questions, '1' = best response, total range 5-25) * Mood/Behavior (7 questions, '5' = best response, total range 7-35) * Quality of Interactions (3 questions, '1' = best response, total range 3-15) * Activity/Sleep (2 questions, '5' = best response for patient's activity level and '1' = best response for patient's sleeping, total range 2-10)

    Time frame: Up to 6 months

  12. Incidence, Severity, Causality and Outcomes of AEs (Serious and Non-serious)

    Incidence of adverse events. SAE = serious adverse event; TEAE = treatment-emergent adverse event

    Time frame: Up to 18 months

  13. Evolution of Laboratory Parameters Change From Baseline to EOT/Week 8

    Number of patients experiencing shifts from baseline in the following relevant laboratory parameters are reported: * Biochemistry: glucose ferritin, C-reactive protein (CRP), liver function (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gamma glutamyl transferase \[γGT\], lactate dehydrogenase \[LDH\], bilirubin, renal function (albumin, creatinine, urea, urea nitrogen), triglycerides * Complete blood count: basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, large unstained cells, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils band form, neutrophils band form/leukocytes, platelets, erythrocytes, leukocytes * Coagulation tests (activated partial thromboplastin time \[aPTT\], aPTT ratio, prothrombin time, prothrombin international normalized ratio \[INR\]), D-dimer, fibrinogen

    Time frame: To Week 8 or End of treatment if before Week 8.

  14. Number of Patients Who Discontinued Emapalumab Treatment

    Number of patients who discontinued emapalumab treatment for safety reasons.

    Time frame: Up to 6 months

Other outcomes

  1. Serum Concentrations of Emapalumab

    The serum concentration of emapalumab will be measured as a function of time to determine the emapalumab PK profile.

    Time frame: Up to Week 8, with data presented at Baseline and EOT/W8

  2. Change in Pharmacodynamic Parameters

    Levels (in ng/L) of total IFNγ (interferon gamma), markers of its neutralization (CXCL9 and CXCL10), and sCD25.

    Time frame: Up to 18 months with data presented at Baseline and EOT/W8

  3. Number of Patients Who Demonstrated a Presence of Circulating Antibodies Against Emapalumab to Determine Immunogenicity

    The presence of circulating antibodies against emapalumab was inferred by positive results for anti-drug antibodies (ADAs).

    Time frame: Up to 1 year follow up post end of treatment with assessments at first dose of emapalumab, Week 4, Week 8, EOT and following treatment at day 100 and at the 1 year follow up visit, with data presented at study day 21 and EOT/Week 8.

07

Results

Posted Mar 12, 2024

Participant flow

Participant flow — Overall Study
MilestoneAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Started1619
Completed99
Not completed710
Withdrew: Death79
Withdrew: Study discontinuation due to other reason01

Outcome measures

PrimaryOverall Response at Week 8 or End of Treatment (if Earlier)

The overall response rate (ORR) of patients achieving either Complete or Partial Response or HLH Improvement, at Week 8 or EOT (whichever occurs earlier).

Time frame:
Up to Week 8
Reported as:
Number · Percentage of participants
Overall Response at Week 8 or End of Treatment (if Earlier)
Percentage of participantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Overall Response at Week 8 or End of Treatment (if Earlier)62.9 (44.9 to 78.5)50.0 (24.7 to 75.3)73.7 (48.8 to 90.9)
Statistical analysis
  • All-treated Analysis Set · Exact binomial · p = 0.0053 · Overall response rate: 62.9 · 95% CI 44.9 to 78.5
  • All-treated Analysis Set - Treatment naïve · Exact binomial · p = 0.2839
  • All-treated Analysis Set - Treatment Experienced · Exact binomial · p = 0.0031
SecondaryOverall Survival at End of Study

Number of patients surviving to the end of the study.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Overall Survival at End of Study
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Alive at end of study19910
Early discontinuation101
SecondaryOverall Survival to HSCT

Number of patients surviving to HSCT.

Time frame:
From start of treatment to HSCT or from start of treatment until 1 year after EOT for patient who did not undergo HSCT
Reported as:
Count of participants · Participants
Overall Survival to HSCT
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Overall Survival to HSCT251213
SecondaryOverall Survival for Patients Receiving HSCT

Number of patients surviving post HSCT.

Time frame:
Up to 1 year post HSCT
Reported as:
Count of participants · Participants
Overall Survival for Patients Receiving HSCT
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Overall Survival for Patients Receiving HSCT1789
SecondaryEvent-free Survival

Number of patients experiencing event-free survival, the duration of which was defined as time from HSCT to date of (whichever occurs first): death from any cause, graft failure, or HLH reactivation.

Time frame:
Up to 1 year post HSCT
Reported as:
Count of participants · Participants
Event-free Survival
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Event-free Survival1688
SecondaryOverall Response at Start of Conditioning

Number of patients achieving either a Complete or Partial Response or HLH Improvement, at start of conditioning (or at last emapalumab infusion if HSCT is not performed).

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Overall Response at Start of Conditioning
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Complete response431
Partial response1156
HLH improvement101
No response19811
SecondaryDuration of Response

Duration of response, i.e., maintenance of the response achieved at any time during the study (with censoring time at start of conditioning for patients with no event) calculated only for patients showing confirmed overall response. Summarized by number of patients experiencing each category of response duration.

Time frame:
Up to 18 months
Reported as:
Median · days
Duration of Response
daysAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Duration of Response61 (29.0 to NA)40 (19.0 to NA)61 (21.0 to NA)
SecondaryTime to Response

Time to first response at any time during the study.

Time frame:
Up to 18 months
Reported as:
Median · days
Time to Response
daysAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Time to Response4 (4.0 to 13.0)5 (4.0 to 21.0)4 (4.0 to 30.0)
SecondaryNumber of Patients Reducing Glucocorticoids by 50% or More of the Baseline Dose During Emapalumab Treatment

Number of patients able to reduce glucocorticoids by 50% or more of the baseline dose during emapalumab treatment.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Number of Patients Reducing Glucocorticoids by 50% or More of the Baseline Dose During Emapalumab Treatment
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Number of Patients Reducing Glucocorticoids by 50% or More of the Baseline Dose During Emapalumab Treatment1587
SecondaryNumber of Patients Proceeding to HSCT

Number of patients able to proceed to HSCT when deemed indicated.

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Number of Patients Proceeding to HSCT
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Number of Patients Proceeding to HSCT231112
SecondaryQuality of Life Assessed Through PedsQL™, Pediatric Quality of Life Inventory™

Assessment of the quality of life using the PedsQL "Pediatric Quality of Life Inventory". The PedsQL uses a 100-point scale ranging from 0 to 100 with higher values indicating better quality of life.

Time frame:
Up to 6 months
Reported as:
Mean · scale on a score
Quality of Life Assessed Through PedsQL™, Pediatric Quality of Life Inventory™
scale on a scoreAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Change from Baseline at EOT/Week 8 - 1-12 months0.208 ± 18.0737-6.514 ± 14.89775.810 ± 19.8220
Change from Baseline at EOT/Week 8 - 13-24 months0.794 ± 4.8152—0.794 ± 4.8152
Change from Baseline at EOT/Week 8 - 2-4 years8.469 ± 9.6897—8.469 ± 9.6897
Change from Baseline at EOT/Week 8 - 8-12 years15.97815.978—
Change from Baseline at EOT/Week 8 - 13-18 years-7.862 ± 13.4760—-7.862 ± 13.4760
SecondaryQuality of Life Assessed Through Behavioral, Affective and Somatic Experiences Scales (BASES)

Assessment of the quality of life using the BASES questionnaire, which is a validated 38-item questionnaire; a reduced nonvalidated 22-item version of the questionnaire is used in an exploratory nature for the secondary endpoint. Subscale scores were calculated using a 5-point Likert scale from 1 to 5 for all questions. Scores for all questions in each subscale were added up and divided by the number of patients in the analysis population to reach the mean score. Subscale scores were calculated for the following domains: * Physical Discomfort (5 questions, '1' = best response, total range 5-25) * Cooperation/Compliance (5 questions, '1' = best response, total range 5-25) * Mood/Behavior (7 questions, '5' = best response, total range 7-35) * Quality of Interactions (3 questions, '1' = best response, total range 3-15) * Activity/Sleep (2 questions, '5' = best response for patient's activity level and '1' = best response for patient's sleeping, total range 2-10)

Time frame:
Up to 6 months
Reported as:
Mean · scale on a score
Quality of Life Assessed Through Behavioral, Affective and Somatic Experiences Scales (BASES)
scale on a scoreAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Physical discomfort10.0 ± 3.579.4 ± 2.9910.5 ± 4.14
Cooperation/compliance9.3 ± 3.029.6 ± 2.769.1 ± 3.4
Mood/behavior20.4 ± 8.8215.1 ± 8.8825.0 ± 6.02
Quality of interactions5.8 ± 2.346.1 ± 2.485.5 ± 2.33
Activity3.1 ± 1.222.7 ± 0.953.4 ± 1.41
Sleep2.1 ± 1.041.8 ± 1.102.3 ± 1.03
SecondaryIncidence, Severity, Causality and Outcomes of AEs (Serious and Non-serious)

Incidence of adverse events. SAE = serious adverse event; TEAE = treatment-emergent adverse event

Time frame:
Up to 18 months
Reported as:
Count of participants · Participants
Incidence, Severity, Causality and Outcomes of AEs (Serious and Non-serious)
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Non-TEAEs15510
TEAEs351619
TEAEs related to study drug936
Mild TEAEs301218
Moderate TEAEs271215
Severe TEAEs311516
TEAEs leading to discontinuation of study drug734
TEAEs with an outcome of death1679
Serious TEAEs321616
Treatment-emergent SAEs related to study drug422
TEAEs with infections291415
Mild infections211011
Moderate infections1587
Severe infections1679
TEAEs with infusion-related reactions734
SecondaryEvolution of Laboratory Parameters Change From Baseline to EOT/Week 8

Number of patients experiencing shifts from baseline in the following relevant laboratory parameters are reported: * Biochemistry: glucose ferritin, C-reactive protein (CRP), liver function (alkaline phosphatase \[ALP\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], gamma glutamyl transferase \[γGT\], lactate dehydrogenase \[LDH\], bilirubin, renal function (albumin, creatinine, urea, urea nitrogen), triglycerides * Complete blood count: basophils, basophils/leukocytes, eosinophils, eosinophils/leukocytes, hematocrit, hemoglobin, large unstained cells, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils band form, neutrophils band form/leukocytes, platelets, erythrocytes, leukocytes * Coagulation tests (activated partial thromboplastin time \[aPTT\], aPTT ratio, prothrombin time, prothrombin international normalized ratio \[INR\]), D-dimer, fibrinogen

Time frame:
To Week 8 or End of treatment if before Week 8.
Reported as:
Count of participants · Participants
Evolution of Laboratory Parameters Change From Baseline to EOT/Week 8
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Albumin: low to within633
Albumin: within to low202
Alkaline phosphatase: low to within514
Alkaline phosphatase: within to low853
Alkaline phosphatase: high to within211
Alanine aminotransferase: within to high312
Alanine aminotransferase: high to within862
Aspartate aminotransferase: within to high303
Aspartate aminotransferase: high to low110
Aspartate aminotransferase: high to within853
Bilirubin: within to low110
Bilirubin: within to high101
Bilirubin: high to within422
Creatinine: low to within101
Creatinine: within to low514
Creatinine: within to high101
Creatinine: high to within211
C-reactive protein: within to high624
C-reactive protein: high to within413
Ferritin: high to low110
Ferritin: high to within532
γGT: within to high312
γGT: high to within431
Glucose: within to high220
Glucose: high to within844
Lactate dehydrogenase: low to within101
Lactate dehydrogenase: within to high422
Lactate dehydrogenase: high to within853
Triglycerides: within to high101
Triglycerides: high to within532
Urea: within to low523
Urea: within to high422
Urea: high to within413
Urea nitrogen: low to within110
Urea nitrogen: within to low110
Urea nitrogen: within to high110
Basophils: low to within101
Basophils: within to high101
Basophils: high to within110
Basophils/leukocytes: high to within110
Eosinophils: low to within312
Eosinophils: within to low110
Eosinophils/leukocytes: within to high211
Hematocrit: low to within945
Hematocrit: within to low523
Hemoglobin: low to within954
Hemoglobin: low to high101
Hemoglobin: within to low514
Large unstained cells: high to within110
Lymphocytes: low to within422
Lymphocytes: within to low633
Lymphocytes: within to high110
Lymphocytes: high to within110
Lymphocytes/leukocytes: within to high110
Lymphocytes/leukocytes: within to low422
Lymphocytes/leukocytes: high to within220
Monocytes: low to within624
Monocytes: low to high303
Monocytes: within to low211
Monocytes: within to high220
Monocytes: high to within202
Monocytes/leukocytes: within to high330
Monocytes/leukocytes: high to within110
Neutrophils band form: low to within936
Neutrophils band form: within to low211
Neutrophils band form: within to high202
Neutrophils band form: high to within110
Neutrophils band form/leukocytes: low to within211
Neutrophils band form/leukocytes: within to low110
Neutrophils band form/leukocytes: within to high110
Platelets: low to within523
Platelets: low to high220
Platelets: within to low312
Platelets: within to high101
Platelets: high to within101
Erythrocytes: low to within844
Erythrocytes: within to low422
Erythrocytes: within to high101
Leukocytes: low to within927
Leukocytes: low to high110
Leukocytes: within to low431
Leukocytes: high to within110
aPTT: low to within211
aPTT: within to low422
aPTT: within to high312
aPTT: high to within431
aPTT ratio: low to within202
aPTT ratio: within to low101
aPTT ratio: within to high202
aPTT ratio: high to within220
D-dimer: within to high404
D-dimer: high to within642
Fibrinogen: low to within1367
Fibrinogen: low to high101
Fibrinogen: within to low211
Fibrinogen: within to high211
Fibrinogen: high to within312
Prothrombin time: within to high312
Prothrombin time: high to within633
Prothrombin INR: within to high101
Prothrombin INR: high to low110
Prothrombin INR: high to within422
SecondaryNumber of Patients Who Discontinued Emapalumab Treatment

Number of patients who discontinued emapalumab treatment for safety reasons.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Number of Patients Who Discontinued Emapalumab Treatment
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Number of Patients Who Discontinued Emapalumab Treatment734
Other pre-specifiedSerum Concentrations of Emapalumab

The serum concentration of emapalumab will be measured as a function of time to determine the emapalumab PK profile.

Time frame:
Up to Week 8, with data presented at Baseline and EOT/W8
Reported as:
Mean · ng/mL
Serum Concentrations of Emapalumab
ng/mLAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Emapalumab serum concentration at Baseline pre-dose14.311 ± 50.271712.899 ± 49.958915.425 ± 51.8562
Emapalumab serum concentration at EOT/Week 8 pre-dose258337.456 ± 231412.7632295521.381 ± 296009.6195231482.400 ± 175589.7297
Emapalumab serum concentration at EOT/Week 8 post-dose142338.620 ± 89464.1682205599.340 ± NA79077.900 ± NA
Other pre-specifiedChange in Pharmacodynamic Parameters

Levels (in ng/L) of total IFNγ (interferon gamma), markers of its neutralization (CXCL9 and CXCL10), and sCD25.

Time frame:
Up to 18 months with data presented at Baseline and EOT/W8
Reported as:
Mean · ng/L
Change in Pharmacodynamic Parameters
ng/LAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Total IFNγ at baseline1112.681 ± 2393.97531356.191 ± 2550.8868920.436 ± 2314.6502
Total IFNγ at EOT/Week 825708.836 ± 41775.889039233.258 ± 60957.756315941.198 ± 14695.7764
CXCL10 at baseline14195.394 ± 37588.507328501.304 ± 54928.01523654.197 ± 7505.8959
CXCL10 at EOT/Week 83203.194 ± 13239.62386355.428 ± 20287.7247926.580 ± 2389.4231
CXCL9 at baseline14113.999 ± 34451.604126695.379 ± 49400.50904181.331 ± 6470.0963
CXCL9 at EOT/Week 82109.078 ± 10100.88024749.055 ± 15555.8338202.428 ± 240.9550
sCD25 at baseline17026.171 ± 13537.895123980.603 ± 13267.583411535.830 ± 11268.1072
sCD25 at EOT/Week 89882.585 ± 8542.041811301.162 ± 8847.80008858.058 ± 8417.5485
Other pre-specifiedNumber of Patients Who Demonstrated a Presence of Circulating Antibodies Against Emapalumab to Determine Immunogenicity

The presence of circulating antibodies against emapalumab was inferred by positive results for anti-drug antibodies (ADAs).

Time frame:
Up to 1 year follow up post end of treatment with assessments at first dose of emapalumab, Week 4, Week 8, EOT and following treatment at day 100 and at the 1 year follow up visit, with data presented at study day 21 and EOT/Week 8.
Reported as:
Count of participants · Participants
Number of Patients Who Demonstrated a Presence of Circulating Antibodies Against Emapalumab to Determine Immunogenicity
ParticipantsAll-treated Analysis SetAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment Experienced
Presence of circulating antibodies at Study Day 21220
Presence of circulating antibodies at End of Treatment/Week 8101

Adverse events

Collected over Signing of ICF until end of long-term follow-up (1 year after either HSCT or the last emapalumab infusion if HSCT was not performed). Through study completion. The average time 285 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All-treated Analysis Set - Treatment naïve7/16 (43.8%)16/16 (100%)14/16 (87.5%)
All-treated Analysis Set - Treatment Experienced9/19 (47.4%)16/19 (84.2%)19/19 (100%)
All-treated Analysis Set16/35 (45.7%)32/35 (91.4%)35/35 (100%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedAll-treated Analysis Set
Condition aggravatedGeneral disorders4/168/1912/35
Multiple organ dysfunction syndromeGeneral disorders1/164/195/35
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/160/193/35
PyrexiaGeneral disorders2/163/195/35
SeizureNervous system disorders0/163/193/35
Febrile neutropeniaBlood and lymphatic system disorders1/163/194/35
Staphylococcal sepsisInfections and infestations2/161/193/35
Respiratory distressRespiratory, thoracic and mediastinal disorders2/162/194/35
Respiratory failureRespiratory, thoracic and mediastinal disorders2/162/194/35
PneumonitisRespiratory, thoracic and mediastinal disorders2/160/192/35
Most frequent other events
Showing 10 of 261
Most frequent other events
EventAll-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedAll-treated Analysis Set
VomitingGastrointestinal disorders7/1610/1917/35
DiarrhoeaGastrointestinal disorders5/1610/1915/35
PyrexiaGeneral disorders6/168/1914/35
HypertensionVascular disorders6/165/1911/35
PainGeneral disorders3/166/199/35
Abdominal painGastrointestinal disorders2/165/197/35
RashSkin and subcutaneous tissue disorders4/164/198/35
StomatitisGastrointestinal disorders2/164/196/35
Mucosal inflammationGeneral disorders1/164/195/35
PruritusSkin and subcutaneous tissue disorders1/164/195/35

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
<=18 years161935
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
Female31114
Male13821
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
Hispanic or Latino303
Not Hispanic or Latino121830
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
American Indian or Alaska Native101
Asian314
Native Hawaiian or Other Pacific Islander101
Black or African American314
White61218
More than one race000
Unknown or Not Reported257
Body Weight (kg)
Body Weight (kg)(kg)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
Mean9.599 ± 10.591513.946 ± 14.435111.959 ± 12.8309
Height/Length (cm)
Height/Length (cm)(cm)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
Mean67.02 ± 27.41683.41 ± 37.79075.96 ± 34.003
Body Surface Area (m^2)
Body Surface Area (m^2)(m^2)All-treated Analysis Set - Treatment naïveAll-treated Analysis Set - Treatment ExperiencedTotal
Mean0.415 ± 0.30220.564 ± 0.41410.497 ± 0.3698
08

Study locations

27 sites
  • Phoenix Children Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045-7106, United States
  • Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology
    Wilmington, Delaware 19803, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Dana-Farber Cancer Institute (DFCI)
    Boston, Massachusetts 02215, United States
  • Spectrum Health Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Texas Children's Hospital - Feigin Center
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98109, United States
  • Hopital Ste-Justine Research Center
    Montréal, QC H3T 1C5, Canada
  • Hospital for Sick Children
    Toronto, ON M5G 1X8, Canada
  • Children's and Women's Health Centre of British Columbia
    Vancouver, V6H 3V4, Canada
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Medical Center- University of Freiburg
    Freiburg, 79106, Germany
  • Universitätsklinikum Eppendorf
    Hamburg, 20246, Germany
  • Istituto Giannina Gaslini
    Genova, 16147, Italy
  • Fondazione MBBM, Ospedale San Gerardo
    Monza, 20900, Italy
  • Ospedale Pediatrico Bambino Gesù
    Rome, 00165, Italy
  • Ospedale della Donna e del Bambino
    Verona, 37126, Italy
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Niño Jesús
    Madrid, 28009, Spain
  • Karolinska University Hospital Huddinge
    Stockholm, 14186, Sweden
  • University Children's Hospital Zurich
    Zürich, CH-8032, Switzerland
  • Leeds Children's Hospital
    Leeds, LS1 3EX, United Kingdom
  • Great Ormond Street Hospital
    London, WC1N 3JH, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Aug 2021, 30 months.

Results were first posted in Mar 2024, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2017
First posted
Oct 18, 2017
StartActual
Feb 6, 2019
Primary completionActual
Aug 18, 2021
CompletionActual
Sep 14, 2022
Results first posted
Mar 12, 2024
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03312751
Responsible party
Sponsor
First posted
Oct 18, 2017
Start date
Feb 6, 2019
Primary completion
Aug 18, 2021
Completion
Sep 14, 2022
Results posted
Mar 12, 2024
Last update
Mar 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emapalumab

Start the discussion